Article

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

2018-01-17

Abstract excerpt

JAK inhibitors have been developed following the discovery of the JAK2 V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL ) also exhibited persistent JAK2 activation. Several type I ATP-competitive JAK inhibitors with different specific...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ffaa74cc-6d3d-5488-81ab-3bf1fe27f00f
DOI: 10.12688/f1000research.13167.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersDOI 10.12688/f1000research.13167.1Read

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read

How many JAK inhibitors in myelofibrosis?Semantic proximity Read

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read